Sutro Biopharma Inc
NASDAQ:STRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sutro Biopharma Inc
NASDAQ:STRO
|
US |
|
I
|
Itau Unibanco Holding SA
SWB:BVXB
|
BR |
|
Capital & Counties Properties PLC
LSE:CAPC
|
UK |
|
RF Industries Ltd
NASDAQ:RFIL
|
US |
|
1
|
11 Bit Studios SA
F:11C
|
PL |
Sutro Biopharma Inc
Sutro Biopharma is a biotechnology company that designs cancer drugs, especially antibody-drug conjugates and other targeted biologic medicines. Its main job is to build drug candidates that can carry a cancer-killing payload directly to tumor cells while trying to spare healthy tissue. The company sells the drugs themselves only if they are approved in the future, so today it is mainly focused on research and development. Its core technology is a cell-free protein manufacturing platform that helps it make and test complex protein-based medicines that can be harder to produce with standard methods. Sutro also works with pharmaceutical partners through collaborations, which can bring in upfront payments, research funding, milestone payments, and royalties if partnered programs succeed. That means part of its business is as a drug developer and part is as a technology partner. Sutro’s main customers are not everyday consumers but cancer patients, hospitals, and drugmakers. In the near term, it depends on research partnerships and financing to support development; in the long run, it would make money from approved medicines and from licensing or sharing rights to its drug candidates. Its role is different because it sits earlier in the drug chain than most biopharma companies: it invents and engineers complex targeted therapies rather than just marketing finished drugs.
Sutro Biopharma is a biotechnology company that designs cancer drugs, especially antibody-drug conjugates and other targeted biologic medicines. Its main job is to build drug candidates that can carry a cancer-killing payload directly to tumor cells while trying to spare healthy tissue. The company sells the drugs themselves only if they are approved in the future, so today it is mainly focused on research and development.
Its core technology is a cell-free protein manufacturing platform that helps it make and test complex protein-based medicines that can be harder to produce with standard methods. Sutro also works with pharmaceutical partners through collaborations, which can bring in upfront payments, research funding, milestone payments, and royalties if partnered programs succeed. That means part of its business is as a drug developer and part is as a technology partner.
Sutro’s main customers are not everyday consumers but cancer patients, hospitals, and drugmakers. In the near term, it depends on research partnerships and financing to support development; in the long run, it would make money from approved medicines and from licensing or sharing rights to its drug candidates. Its role is different because it sits earlier in the drug chain than most biopharma companies: it invents and engineers complex targeted therapies rather than just marketing finished drugs.
Strategic Shift: Sutro is deprioritizing its investment in luvelta, focusing resources on three next-generation ADC preclinical programs, including STRO-004, STRO-006, and a dual-payload ADC.
Restructuring: The company will cut its workforce by nearly 50% and externalize cell-free manufacturing, aiming to extend its cash runway into at least Q4 2026.
Luvelta Out-Licensing: Sutro is actively seeking a partner to take over luvelta’s development, emphasizing that the decision to deprioritize was due to limited internal resources, not lack of faith in luvelta’s potential.
Clinical Pipeline: IND filing for STRO-004 is planned for the second half of 2025, with initial clinical data expected in 2026–2027. Additional INDs for STRO-006 and the dual-payload ADC are planned for 2026 and 2027.
Cost Savings: Management forecasts a dramatic decrease in expenditures starting in 2025 due to the winding down of luvelta and restructuring actions.
Partnerships: Ongoing discussions are targeting out-licensing of luvelta, with continued openness to additional collaborations and nondilutive funding for the pipeline.
